Regulatory news
Access the latest market announcements, updates and disclosures from Diaceutics.
Filter by:
report
Annual Report and Financial Statements for the year ended 31 December 2025
presentations
Corporate Overview Presentation - September 2026
presentations
Full Year 2025 Results Analyst Presentation
presentations
H1 2025 Interim Results Analyst Presentation
presentations
H1 2026 Interim Results Presentation
webinars
Virtual Capital Markets Event
webinars
PMx Capital Markets Webinar
report
Diaceutics PLC financial year 2022 results & outlook
report
Diaceutics PLC Annual Report 2022
report
Diaceutics PLC Annual Report 2023
webinars
Virtual Capital Markets Event Presentation — Helping Pharma Find Patients
report
Annual Report and Financial Statements for the year ended 31 December 2024
report
Diaceutics Corporate Overview Presentation December 2025
report
Interim Report 2019
report
Diaceutics Annual Report 2019
report
Diaceutics PLC Annual Report 2020
report
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces its unaudited interim results for the six months ended 30 June 2021
presentations
Diaceutics PLC Financial Year 2021 Results Presentation
report
Diaceutics PLC Annual Report 2021
presentations
Diaceutics PLC H1 2022 Results presentation Slide Deck
results
Interim Report June 2022
results
Diaceutics releases 2023 trading update
results
Diaceutics releases trading update for period ending 30 June 2023
results
Diaceutics provides trading statement for year ended 31 Dec 22
results
Diaceutics releases interim results for period ended 30 June 2022
results
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces its unaudited interim results for the six months ended 30 June 2021
results
Final Results
results
PDMR Shareholding/Share Incentive Plan and Total Voting Rights
report
Annual Report and Financial Statements for the year ended 31 December 2025
presentations
Diaceutics Corporate Overview Presentation May / June 2026
results
DXRX platform contract win
results
Diaceutics announces the launch of its real-time Test Signal service in the US
results
US$1m contract with leading life sciences company for data feed from the DXRX platform
results
Nick Roberts joins Diaceutics as Chief Financial Officer
results
Diaceutics CEO, Peter Keeling named in The Business & Finance CEO 100 Index 2022
report
Notice of Interim Results - Upcoming Investor and Analyst Presentations
results
US $7 million multi-year enterprise engagements for subscription data services
results
Diaceutics enters into strategic alliance with KPMG
INVESTOR ALERTS
Sign up to receive the latest Diaceutics investor news, reports and regulatory announcements.
EXPLORE INVESTOR RESOURCES
Results and presentations
Access the latest reports, results materials and investor presentations.
VIEW RESULTS